SCHEMBL17788771

SCHEMBL17788771

Cc1cc(-c2ncn(/C=C(/C(=O)O)c3cncnc3)n2)cc(C(F)(F)F)c1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
XPO1 O14980 14/20 0.71
RANBP1 P43487 1/20 0.71
KCNH2 Q12809 1/20 0.71
ESR1 P03372 1/20 0.43
HTR1A P08908 1/20 0.43
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43
HRH1 P35367 1/20 0.43
PDE4D Q08499 1/20 0.43
SLC29A1 Q99808 1/20 0.43
NOTUM Q6P988 1/20 0.32
EGFR P00533 2/20 0.31
KDR P35968 2/20 0.31
FGFR1 P11362 1/20 0.31
ABL1 P00519 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17788770 1.00 XPO1 (0.71) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788772 1.00 XPO1 (0.71) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL16325038 0.93 XPO1 (0.82) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL16322954 0.93 XPO1 (0.82) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17790542 0.93 XPO1 (0.82) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788773 0.91 XPO1 (0.86) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL16361454 0.91 XPO1 (0.86) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788774 0.91 XPO1 (0.86) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788877 0.89 XPO1 (0.56) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL26326437 0.89 XPO1 (0.56) XPO1RANBP1KCNH2ESR1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155317-A1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Karyopharm Therapeutics Inc. 2018-06-07 US disclosed
US-9738624-B2 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. (US) 2017-08-22 US disclosed
US-20160152596-A1 Nuclear Transport Modulators and Uses Thereof Karyopharm Therapeutics Inc. (US) 2016-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155317-A1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF XPO1, XPO5, XPOT XPO1 1/4885RANBP1 159/4885KCNH2 4379/4885
US-20160152596-A1 Nuclear Transport Modulators and Uses Thereof XPO5, XPO1, XPOT XPO1 2/4885RANBP1 144/4885KCNH2 4320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.